158 related articles for article (PubMed ID: 23984812)
1. Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts.
Kristian A; Revheim ME; Qu H; Mælandsmo GM; Engebråten O; Seierstad T; Malinen E
Acta Oncol; 2013 Oct; 52(7):1566-72. PubMed ID: 23984812
[TBL] [Abstract][Full Text] [Related]
2. Dynamic 2-Deoxy-2-[
Kristian A; Holtedahl JE; Torheim T; Futsaether C; Hernes E; Engebraaten O; Mælandsmo GM; Malinen E
Mol Imaging Biol; 2017 Apr; 19(2):271-279. PubMed ID: 27541026
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.
Humbert O; Riedinger JM; Vrigneaud JM; Kanoun S; Dygai-Cochet I; Berriolo-Riedinger A; Toubeau M; Depardon E; Lassere M; Tisserand S; Fumoleau P; Brunotte F; Cochet A
J Nucl Med; 2016 Nov; 57(11):1707-1712. PubMed ID: 27103025
[TBL] [Abstract][Full Text] [Related]
4. GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[
Capozza M; Anemone A; Dhakan C; Della Peruta M; Bracesco M; Zullino S; Villano D; Terreno E; Longo DL; Aime S
Mol Imaging Biol; 2022 Feb; 24(1):126-134. PubMed ID: 34383241
[TBL] [Abstract][Full Text] [Related]
5. (18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy.
Guo J; Guo N; Lang L; Kiesewetter DO; Xie Q; Li Q; Eden HS; Niu G; Chen X
J Nucl Med; 2014 Jan; 55(1):154-60. PubMed ID: 24232871
[TBL] [Abstract][Full Text] [Related]
6. Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis.
Røe K; Aleksandersen TB; Kristian A; Nilsen LB; Seierstad T; Qu H; Ree AH; Olsen DR; Malinen E
Acta Oncol; 2010 Oct; 49(7):914-21. PubMed ID: 20831478
[TBL] [Abstract][Full Text] [Related]
7. Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and
Nguyen-Thu H; Hanaoka H; Nakajima T; Yamaguchi A; Nguyen-Cong T; Kartamihardja AAP; Tsushima Y
Breast Cancer; 2018 May; 25(3):334-342. PubMed ID: 29357023
[TBL] [Abstract][Full Text] [Related]
8. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
Fleuren ED; Versleijen-Jonkers YM; Roeffen MH; Franssen GM; Flucke UE; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
Int J Cancer; 2014 Dec; 135(12):2770-82. PubMed ID: 24771207
[TBL] [Abstract][Full Text] [Related]
9. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
[TBL] [Abstract][Full Text] [Related]
10. Variability of dynamic 18F-FDG-PET data in breast cancer xenografts.
Pitman KE; Rusten E; Kristian A; Malinen E
Acta Oncol; 2015; 54(9):1399-407. PubMed ID: 26217987
[TBL] [Abstract][Full Text] [Related]
11. Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.
Corroyer-Dulmont A; Pérès EA; Petit E; Guillamo JS; Varoqueaux N; Roussel S; Toutain J; Divoux D; MacKenzie ET; Delamare J; Ibazizène M; Lecocq M; Jacobs AH; Barré L; Bernaudin M; Valable S
Neuro Oncol; 2013 Jan; 15(1):41-56. PubMed ID: 23115160
[TBL] [Abstract][Full Text] [Related]
12.
Liu H; Sun H; Zhang B; Liu S; Deng S; Weng Z; Zuo B; Yang J; He Y
Breast Cancer; 2020 May; 27(3):372-380. PubMed ID: 31781983
[TBL] [Abstract][Full Text] [Related]
13. Glucose metabolism gene expression patterns and tumor uptake of ¹⁸F-fluorodeoxyglucose after radiation treatment.
Wilson GD; Thibodeau BJ; Fortier LE; Pruetz BL; Galoforo S; Baschnagel AM; Chunta J; Oliver Wong CY; Yan D; Marples B; Huang J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):620-7. PubMed ID: 25304950
[TBL] [Abstract][Full Text] [Related]
14. Magnetic Resonance Imaging Is More Sensitive Than PET for Detecting Treatment-Induced Cell Death-Dependent Changes in Glycolysis.
Hesketh RL; Wang J; Wright AJ; Lewis DY; Denton AE; Grenfell R; Miller JL; Bielik R; Gehrung M; Fala M; Ros S; Xie B; Hu DE; Brindle KM
Cancer Res; 2019 Jul; 79(14):3557-3569. PubMed ID: 31088837
[TBL] [Abstract][Full Text] [Related]
15. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
Moestue SA; Huuse EM; Lindholm EM; Bofin A; Engebraaten O; Mælandsmo GM; Akslen LA; Gribbestad IS
J Magn Reson Imaging; 2013 Nov; 38(5):1043-53. PubMed ID: 23908122
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.
Zhu AX; Meyerhardt JA; Blaszkowsky LS; Kambadakone AR; Muzikansky A; Zheng H; Clark JW; Abrams TA; Chan JA; Enzinger PC; Bhargava P; Kwak EL; Allen JN; Jain SR; Stuart K; Horgan K; Sheehan S; Fuchs CS; Ryan DP; Sahani DV
Lancet Oncol; 2010 Jan; 11(1):48-54. PubMed ID: 19932054
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
[TBL] [Abstract][Full Text] [Related]
18. Preclinical PERCIST and 25% of SUV
Savaikar MA; Whitehead T; Roy S; Strong L; Fettig N; Prmeau T; Luo J; Li S; Wahl RL; Shoghi KI
J Nucl Med; 2020 Jun; 61(6):842-849. PubMed ID: 31757841
[TBL] [Abstract][Full Text] [Related]
19. [18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.
Raccagni I; Belloli S; Valtorta S; Stefano A; Presotto L; Pascali C; Bogni A; Tortoreto M; Zaffaroni N; Daidone MG; Russo G; Bombardieri E; Moresco RM
PLoS One; 2018; 13(5):e0197754. PubMed ID: 29791503
[TBL] [Abstract][Full Text] [Related]
20. Influx rate of
Pitman KE; Alluri SR; Kristian A; Aarnes EK; Lyng H; Riss PJ; Malinen E
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2190-2198. PubMed ID: 31264167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
